Literature DB >> 30450569

Long noncoding RNA STXBP5-AS1 inhibits cell proliferation, migration, and invasion via preventing the PI3K/AKT against STXBP5 expression in non-small-cell lung carcinoma.

Jingyu Huang1, Nianlin Xie2, Hu Huang3, Jie Yao4, Weidong Hu1.   

Abstract

Long noncoding RNAs participate in carcinogenesis and tumor progression in non-small-cell lung carcinoma (NSCLC), but the mechanisms underlying NSCLC tumorigenesis remain to be fully elucidated. Here, we reported the functional role and potential mechanism of long noncoding RNA syntaxin-binding protein 5-antisense RNA 1 (STXBP5-AS1) in NSCLC. First, our data revealed that the expression levels of STXBP5-AS1 in 31 NSCLC tissues were lower than in adjacent tissues using quantitative polymerase chain reaction (qPCR) and its expression was significantly associated with tumor metastasis of NSCLC patients. Moreover, CCK-8, scratch wound healing and transwell assay suggested that upregulation of STXBP5-AS1 repressed the proliferation, migration, and invasion in A549, NCI-H292, and NCI-H460 cells. To explore the potential mechanism of STXBP5-AS1 in NSCLC, we first investigated the relationship among STXBP5-AS1, STXBP5, and AKT1 in A549 cells. Results indicated that STXBP5-AS1 was negatively related with STXBP5 and AKT1 at messenger RNA expression level using qPCR. In addition, we observed that STXBP5-AS1 had reverse effects on the protein levels of STXBP5 and phosphorylated AKT1 (p-AKT1) in A549 cells via Western blot assay, despite no significant effects on AKT1. Subsequently, LY294002, as the phosphatidylinositol 3 kinase/protein kinase B (PI3K/AKT) pathway inhibitor, was used to further confirm the regulatory mechanism of STXBP5-AS1, which showed that knockdown of STXBP5-AS1 could rescue the expression of STXBP5 and p-AKT1 protein expression levels in A549 cells. Taken together, our results suggested that STXBP5-AS1, as a tumor suppressor, inhibits cell proliferation, migration, and invasion by preventing the PI3K/AKT against STXBP5 expression in NSCLC.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  STXBP5-antisense RNA 1; long noncoding RNA; non-small-cell lung carcinoma; phosphatidylinositol 3 kinase/protein kinase B; syntaxin-binding protein 5

Year:  2018        PMID: 30450569     DOI: 10.1002/jcb.28023

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  6 in total

1.  Long Noncoding RNA SNHG7 Accelerates Proliferation, Migration and Invasion of Non-Small Cell Lung Cancer Cells by Suppressing miR-181a-5p Through AKT/mTOR Signaling Pathway.

Authors:  Liping Li; Dan Ye; Liang Liu; Xiaoju Li; Jun Liu; Shengtian Su; Wenjing Lu; Zhigao Yu
Journal:  Cancer Manag Res       Date:  2020-09-10       Impact factor: 3.989

2.  Long noncoding RNA STXBP5-AS1 inhibits cell proliferation, migration, and invasion through inhibiting the PI3K/AKT signaling pathway in gastric cancer cells.

Authors:  Dongzhi Cen; Hu Huang; Liu Yang; Kai Guo; Jinshan Zhang
Journal:  Onco Targets Ther       Date:  2019-03-08       Impact factor: 4.147

3.  Identification of Novel lncRNA Markers in Glioblastoma Multiforme and Their Clinical Significance: A Study Based on Multiple Sequencing Data.

Authors:  Youwei Li; Dongsheng Guo
Journal:  Onco Targets Ther       Date:  2020-02-04       Impact factor: 4.147

4.  LncRNA STXBP5-AS1 suppresses stem cell-like properties of pancreatic cancer by epigenetically inhibiting neighboring androglobin gene expression.

Authors:  Shi Chen; Long Huang; Ge Li; Funan Qiu; Yaodong Wang; Can Yang; Jingjing Pan; Zhangwei Wu; Jiangzhi Chen; Yifeng Tian
Journal:  Clin Epigenetics       Date:  2020-11-07       Impact factor: 6.551

5.  Genetic variants are identified to increase risk of COVID-19 related mortality from UK Biobank data.

Authors:  Jianchang Hu; Cai Li; Shiying Wang; Ting Li; Heping Zhang
Journal:  Hum Genomics       Date:  2021-02-03       Impact factor: 4.639

6.  Genetic variants are identified to increase risk of COVID-19 related mortality from UK Biobank data.

Authors:  Jianchang Hu; Cai Li; Shiying Wang; Ting Li; Heping Zhang
Journal:  medRxiv       Date:  2020-11-09
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.